Oncoinvent ASA
ONCIN
Rangering i aksjer
#27150
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to... Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
Aksjekurs
$7.15
Markedsverdi
$32.01M
Endring (1 dag)
0.00%
Endring (1 år)
6,383.25%
Land
NO
Handel Oncoinvent ASA (ONCIN)
Kategori
Healthcare
Aksjeprishistorikk for Oncoinvent ASA (ONCIN)
Høyeste sluttskurs: $9.10 den 2026-09-01
Laveste sluttskurs: $27.86 den 2017-12-01
Laveste sluttskurs: $27.86 den 2017-12-01
Aksjeprishistorikk for Oncoinvent ASA fra 2017 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | 268.35% |
| 2025 | 32.73% |
| 2024 | -64.40% |
| 2023 | -90.91% |
| 2022 | 4.70% |
| 2021 | -41.35% |
| 2020 | 114.55% |
| 2019 | -57.70% |
| 2018 | 64.64% |
| 2017 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $536.98 | 25.92% |
US
|
|
| $224.77 | 737.11% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $876.75 | 7.69% |
NL
|
